AmiSulpride is a substituted benzamide which shows great efficacy in Schizophrenia and Manic patients. It also can be an effective anti-depressant and anti-anhedonic , in some cases. However, despite being an effective serotonin 5-HT 7 receptor antagonist and dopamine autoreceptor blocker (thus an effective and unique drug overall) -it has, like other anti-psychotics - a strong prolactin boosting effect. Which needs to be remedied to prevent or reverse hormone deficiencies which may occur while taking the medication.
There are a number of ways to do this.
This is my recommended supplement stack to counter and eliminate Amisulpride's prolactin-ogenic effects. While preserving the benefits of the drug.
1.) Pyridoxal-5-Phosphate : This is a highly BIOAVAILABLE form of Vitamin-B6 which readily crosses the blood-brain-barrier where it can then rapidly reduce Pituitary Prolactin (1) (2) (3) and directly stimulate the tuberoinfundibular networks of dopamine neurons and projections (4) (5) (6) (7).
My recommended LAB-TESTED P5P supplement is below.
STUDY IS ALSO BELOW FOR YOUR CONVENIENCE
Hi. Does this thing work? I had great results with amisulpride but had to quit because I had elevated prolactin levels.
ReplyDeleteYes, it works Unknown, you just have to follow directions below. Read my reply to Petar's comment below, refresh page first. I know, Amisulpride is a great drug if not for the Prolactin effects. Though, at higher doses you gotta be careful of QTc interval prolongation, especially if you are a female {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623652/}.
DeleteWhat dosages of every supplement would you recommend? Best regards. Peter
ReplyDeleteP5P; 50 mg twice a day.
DeletePantethine; 250 mg 3 x / day.
American Ginseng; Generally 1000 mg or 1 Gram per day.
Thank you for your help. Do you take amisulpride?
ReplyDeleteOff and On, Yes. I use it for occasional Anhedonia/Depression though. It works great for both. Unfortunately, any dose of it raises Prolactin even 50 mg - 100 mg.
Delete--> http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1819.2011.02296.x/pdf